Press

Levitee Labs Enters into Credit Facility For Up To $12 Million

Oct 21 • 6 min read

Quick Take: Levitee will utilize the proceeds from the Loan to support their prospective future acquisitions of several assets in the clinics, pharmacies and mental health space as well as for working capital purposes. Levitee Labs Inc. (CSE: LVT) (OTCMKTS: LVTTF), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to…

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Oct 20 • 3 min read

Quick Take: Numinus Bioscience has successfully developed PSYBINA™ from Psilocybe species using IP technology related to the production of extracts and downstream derivatives and formulations from Psychoactive Species Cultured Mycelium Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally…

PharmaDrug Commences Trading on the OTCQB Market in the United States

Oct 20 • 2 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has qualified for trading on the OTCQB Venture Market (the “OTCQB”) operated by the OTC Markets Group Inc. The Company’s…

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

Oct 20 • 5 min read

Quick Take: Investigator-initiated study shows remission in major depression symptoms for 50% of participants COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients. Within one…

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Oct 20 • 2 min read

Quick Take: The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 74th pre-clinical study as it…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441